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ABSTRACT
Cancer cells reprogram their metabolism and energy production to sustain 
increased growth, enable metastasis and overcome resistance to cancer treatments. 
Although primary roles for many metabolic proteins have been identified, some are 
promiscuous in regards to the reaction they catalyze. To efficiently target these 
enzymes, a good understanding of their enzymatic function and structure, as well 
as knowledge regarding any substrate or catalytic promiscuity is required. Here 
we focus on the characterization of human 3-phosphoglycerate dehydrogenase 
(PHGDH). PHGDH catalyzes the NAD+-dependent conversion of 3-phosphoglycerate 
to phosphohydroxypyruvate, which is the first step in the de novo synthesis pathway 
of serine, a critical amino acid for protein and nucleic acid biosynthesis. We have 
investigated substrate analogues to assess whether PHGDH might possess other 
enzymatic roles that could explain its occasional over-expression in cancer, as well 
as to help with the design of specific inhibitors. We also report the crystal structure 
of the catalytic subunit of human PHGDH, a dimer, solved with bound cofactor in one 
monomer and both cofactor and L-tartrate in the second monomer. In vitro enzyme 
activity measurements show that the catalytic subunit of PHGDH is still active and that 
PHGDH activity could be significantly inhibited with adenosine 5’-diphosphoribose.
INTRODUCTION
3-Phosphoglycerate dehydrogenase (PHGDH) 
catalyzes the first step in the de novo serine synthesis 
pathway, i.e. the NAD+-dependent conversion of 
3-phosphoglycerate (3-PG) to phosphohydroxypyruvate 
(PHP). PHGDH diverts the glycolytic flux towards 
producing serine, which in turn is metabolized and 
incorporated into a variety of biomolecules (Figure 1A) 
including glycine, thereby providing a major source 
of one-carbon units for the synthesis of purine and 
pyrimidine nucleotides.
Normal cells metabolize glucose via glycolysis 
to pyruvate, which then can be further oxidized in the 
tricarboxylic acid cycle to carbon dioxide and water with 
concomitant synthesis of ATP. Interestingly, cancer cells 
mainly metabolize glucose through fermentation even in 
the presence of saturating amounts of oxygen, resulting in 
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increased lactate production and a reduced ATP yield [1]. 
This upregulation of aerobic glycolysis – termed “Warburg 
effect” after its discoverer Otto Warburg - results in less 
energy in the form of ATP from each glucose molecule. 
Figure 1: L-Serine synthesis pathway and basic domain structure of PHGDH. (A) 3-Step synthesis scheme of endogenous 
L-serine starts with the oxidation of 3-phosphoglycerate to 3-phosphohydroxypyruvate by PHGDH and simultaneous reduction of the 
cofactor NAD+ to NADH. The subsequent transamination reaction is catalyzed by phosphoserine aminotransferase (PSAT), which uses 
glutamate (Glu) as nitrogen donor and thereby produces phosphoserine and α-ketoglutarate (αKG). Dephosphorylation of phosphoserine 
by phosphoserine phosphatase (PSPH) gives rise to L-serine. (B) Basic domain structure found within the three enzyme types of PHGDH 
shaded by domain. Additional amino acids at the N-terminus are not explicitly shown as variations in length and composition of this part 
of the protein depend on the species. Two forms of the type III enzyme exist depending on whether lysine (type K) or histidine (type H) 
is present at the active site [8] (left). Crystal structures of representative family members of the different types of PHGDH. For a better 
comparison, all enzymes are shown as dimers, although active PHGDH from M. tuberculosis and E. coli form a tetramer. The substrate- and 
nucleotide-binding domain is shown in green/rose, the ASB domain is shown in magenta/brown and the ACT domain is shown in blue/
yellow. If present in the crystal, the cofactor NAD+ is depicted in spheres and colored by atom type (carbon in green) (right).
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However, it also allows for the diversion of the glycolytic 
flux into biomass generation, which is of particular 
importance for highly proliferating cells such as cancer 
cells. The Warburg effect is an exploitable difference 
between normal and cancer cells and provides new 
avenues for targeting cancer. Against this background, 
PHGDH, as a major enzyme in the diversion of glycolytic 
flux towards serine synthesis, is of particular interest.
Recent work highlighted the importance of 
human PHGDH in certain cancer types with amplified 
PHGDH, e.g. breast cancer and melanoma, with PHGDH 
knockdown resulting in reduced cancer cell growth [2-4, 
10]. This sensitivity indicates a potential therapeutic use 
for PHGDH inhibitors in tumors expressing high levels 
of the target enzyme. In this context, recently developed 
PHGDH inhibitors have shown promising results in the 
setting of cells with high PHGDH expression/ PHGDH 
amplification [5, 6].
PHGDH is ubiquitously expressed in all organisms, 
and exists in at least three different basic structural forms, 
referred to as type I, II and III (Figure 1B) [7]. These 
forms do not appear to be strictly life-domain specific as 
mammalian PHGDH shows structural homology with the 
enzyme from the pathogenic bacterium Mycobacterium 
tuberculosis. Both the human and the mycobacterial 
enzymes belong to the structurally most complex type, 
type I. All three types of PHGDH contain two common 
domains: the substrate-binding domain and the cofactor-
binding domain. Type I enzymes contain two additional 
regulatory domains, the ACT (aspartate kinase-chorismate 
mutase-tyrA prephenate dehydrogenase) and ASB 
(allosteric substrate binding) domains. For certain species, 
the ACT domain has been reported to function as a binding 
site for serine to provide feedback inhibition, although this 
regulatory mechanism could not be confirmed for human 
PHGDH [8].
To date, no full-length crystal structure of any 
mammalian PHGDH is known, although a structure 
has been solved for the closely related M. tuberculosis 
PHGDH (PDB 1YGY) [9]. PHGDH from M. tuberculosis 
crystallizes as a tetramer in which the catalytic domains 
adopt the same conformation in all four subunits, whereas 
the regulatory domains adopt differing conformations. 
For human PHGDH, a structure of the core domain 
comprising the cofactor-binding site (amino acids (aa) 93-
298) has been elaborated as a tool for a fragment-based 
inhibitor design [10]. A structure of the complete catalytic 
subunit of human PHGDH (sPHGDH, aa 3-314) (PDB 
2G76, http://www.thesgc.org/structures/2g76#mandm) 
has also been deposited. Unlike M. tuberculosis PHGDH, 
human sPHGDH formed a dimer rather than a tetramer in 
the crystal, probably due to the truncated protein lacking 
the regulatory domains. sPHGDH was crystallized in the 
presence of 0.1 M malate, and D-malate was observed 
bound in the active site. Malate, an analogue of the 
substrate 3-PG, was shown to be favorably aligned for the 
catalytic reaction, including the formation of a salt bridge 
between the carboxylic group of malate and Arg235 of 
the enzyme [8]. Thus, PHGDH might catalyze a reaction 
with malate under certain environmental conditions. 
Recently, human PHGDH was also shown to be able to 
reduce α-ketoglutarate, a structural analogue of PHP, 
to 2-hydroxyglutarate (2-HG), both in vitro and in the 
PHGDH-amplified breast cancer cell line MDA-MB-468 
[11].
These findings strongly suggest that PHGDH 
shows a substrate and catalytic promiscuity, and 
alternative substrates or reactions might become relevant 
under certain biological conditions. This promiscuity 
of PHGDH could be particularly relevant in explaining 
the role of PHGDH in cancer and may suggest PHGDH 
as a tractable target for inhibitor design. Although the 
main role identified for PHGDH so far is in contributing 
to serine synthesis, this might not explain why certain 
cancers seem to rely on PHGDH, as serine is also taken 
up exogenously. The existence of an additional function 
is further suggested by the observation that PHGDH-
depletion in PHGDH-amplified cells results in decreased 
cell proliferation that cannot be rescued through excessive 
addition of serine in the cell media [2, 4].
Here, in order to better understand the substrate and 
catalytic promiscuity of human PHGDH and to identify 
other potential roles of PHGDH that might be relevant in 
diseases, such as cancer, we have developed and applied 
functional and binding assays for PHGDH, and have 
solved structures for the catalytic domain in complex 
with its cofactor NAD+ both alone and together with the 
substrate analogue L-tartrate. With these tools, we have 
investigated the properties of substrate and co-factor 
analogues that are required to permit binding to sPHGDH, 
revealing a remarkably permissive active site that might be 
exploited in drug discovery.
RESULTS
Enzyme activity assay for PHGDH
In its natural environment, PHGDH catalyzes 
the oxidation of 3-PG to PHP, using NAD+ as oxidant. 
However, as PHGDH has a 400-fold higher affinity 
for NADH than NAD+, as determined by isothermal 
titration calorimetry (Figure 2), previously reported 
spectrophotometric PHGDH activity assays have mainly 
measured its activity in the direction of NADH oxidation 
[12, 13]. To perform the assay in this non-physiological 
direction, PHP is needed as substrate in addition to the 
cofactor NADH. Because PHP is no longer commercially 
available, it has become desirable to generate an assay 
that works in the physiological “forward” direction of 
NAD+ reduction. For the reaction to proceed in this 
direction, at least one product of the reaction (NADH or 
PHP) must be continuously removed from the reaction 
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mixture. To characterize PHGDH activity in kinetic 
studies, we developed an assay in which the PHGDH-
catalyzed reaction was coupled to a resazurin reduction 
reaction that uses NADH as cofactor, allowing for the 
continuous regeneration of NAD+ (Figure 3A). Using this 
assay, a Km value of 186.7 ± 16.1 μM was determined 
for the oxidation of 3-PG (Supplementary Figure 1). 
Under the same reaction conditions, a truncated form of 
PHGDH (termed sPHGDH, residues 3-314, comprising 
the substrate and cofactor-binding domains) was shown to 
retain 75 % activity compared to PHGDH, despite lacking 
the regulatory ASB and ACT domains (Figure 3B).
ADPR is an NAD+ competitive inhibitor of 
PHGDH
One possible approach to the targeting of PHGDH 
for anticancer drug discovery would be to develop a 
competitive inhibitor of cofactor binding. To confirm 
the feasibility of this approach, we have investigated the 
inhibitory mechanism of ADP-ribose (ADPR), a cofactor 
analogue that has been reported previously to be a 
competitive inhibitor of a different dehydrogenase, rabbit 
glyceraldehyde dehydrogenase [14].
In the in vitro enzyme activity assay, ADPR 
was able to inhibit full-length PHGDH activity by 
50 % at the maximum tested dose of 120 μM, without 
affecting the coupled NADH recycling reaction (Figure 
3C, Supplementary Figure 2). In addition, ADPR at a 
concentration of 120 μM also inhibited the activity of 
sPHGDH by about 40 %, showing that the effect of ADPR 
is independent of the regulatory domains of PHGDH, 
which together with the structural similarity of NAD+ and 
ADPR, suggested competitive inhibition. This hypothesis 
was confirmed by classical Michaelis-Menten kinetics 
of the PHGDH-catalyzed reaction in the presence of 
increasing amounts of APDR, showing similar Vmax (31.4 
± 1.2 pmol min-1) and Km (11.4 ± 2.1 μM) values (Figure 
3D).
Synergistic binding of cofactor, substrate and 
substrate analogues
The binding of 3-PG (1), DL-malate (3) and 
other substrate and product analogues was investigated 
using differential scanning fluorimetry. The substrate 
analogues were similar in size to 3-PG and all contained 
a 2-hydroxypropanoic acid moiety (Figure 4A). Although 
PHP (6), the physiological binding partner of PHGDH, 
was not available commercially, two PHP analogues that 
share with PHP the 2-oxopropanoic acid moiety, namely 
α-ketoglutarate (7) and pyruvate (8), could be tested 
(Figure 5). Of the substrate and product analogues tested, 
only 3-PG (1) and α-ketoglutarate (7) induced a shift in 
the melting temperature of PHGDH greater than or equal 
to 0.5 °C, and only the natural substrate 3-PG (1) resulted 
in a statistically significant increase in Tm of PHGDH of 
2.5 ± 0.6 °C (Figure 4B). Although DL-malate (3) was not 
seen to bind to PHGDH on its own in this assay, binding 
could be detected in the presence of NAD+, indicating a 
synergistic binding mechanism. The increase in Tm seen 
with 0.2 mM NAD+ alone was 0.9 ± 0.7 °C, whereas in 
combination with DL-malate (3) this value increased to 
2.2 ± 0.7 °C (Supplementary Figure 4). A similar effect 
was seen upon combination of NAD+ and 3-PG (1) with 
a significant increase in melting temperature of 4.5 ± 0.7 
°C. This synergistic stabilization effect seen upon co-
incubation of NAD+ with the natural substrate 3-PG (1) 
or the analogue DL-malate (3) was unique to the oxidized 
cofactor and was not seen when combining NADH with 
Figure 2: Binding of NAD+ and NADH to PHGDH as investigated by ITC. (A) 0.5 mM NADH or (B) 5 mM NAD+ was titrated 
into 0.05 mM PHGDH in 25 mM HEPES, pH 7.5, 100 mM NaCl and 0.5 mM TCEP. Top panel: raw data for 1 x 0.5 μL, followed by 17 x 
2 μL injections of NADH or NAD+ into the isothermal cell containing 0.05 mM PHGDH. Data were corrected for heat of cofactor dilution 
by subtracting the heats from cofactor to buffer titration. Bottom panel: integrated heats from the peaks in the top panel plotted against the 
molar ratio of cofactor to PHGDH. The line of best fit to the data was plotted as obtained by non-linear regression using the built-in one-site 
fit model of the ORIGIN software. (C) Data obtained from the one-site fit model in ORIGIN. Stoichiometry of the reaction (= number of 
binding sites, N), changes in entropy (ΔS) and enthalpy (ΔH) as well as the association constant (Ka) were determined. Binding constant 
(KD) was calculated by taking the reciprocal of the Ka.
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substrate analogues. However, the increase in Tm seen in 
the presence of 0.2 mM NADH alone (9.3 ± 0.5 °C) was 
much more prominent, potentially masking stabilization 
effects due to substrate/ product (analogue) binding 
(Figure 4B).
Co-crystal structure of sPHGDH with NAD+ 
and L-tartrate reveals a domain movement upon 
substrate binding
Although co-crystallization of sPHGDH with 
3-PG and different substrate analogues was attempted, 
sPHGDH only co-crystallized with NAD+ and L-tartrate 
(Table 1, PDB 5N6C). In agreement with the deposited 
structure of sPHGDH, two molecules were present in the 
crystallographic asymmetric unit (ASU). However, while 
both molecules had NAD+ bound to the cofactor sites, 
L-tartrate was only present in one molecule, allowing 
comparison of substrate-bound and unbound states. In 
both domains, NAD+ was bound in the same way, forming 
various hydrogen bonds with the enzyme (Figure 5A). 
The nicotinamide moiety interacted with the backbone 
of the protein (A285 and C233), but also with the side 
chain of D259. The hydroxyl-groups of the sugar moieties 
were also involved in hydrogen bonds with the protein 
backbone (T206) and side chain of D174. The phosphate 
linker interacted with the main chain of R154 and I155 
and also the side chain of R154 (Figure 5A).
The substrate analogue, L-tartrate, interacted with 
both the lid and the core domain of sPHGDH, through 
a network of hydrogen bonds (Figure 5B). L-Tartrate 
formed hydrogen bonds to R235, H282 and A285 of the 
core domain and to R53, S54, R74, T77 and Q291 of the 
lid domain. In the absence of L-tartrate, the lid domain, 
which otherwise closed over the substrate-binding 
site, underwent a rigid domain movement. In order to 
characterize the movement, the two molecules in the ASU 
were compared using the DynDom webserver [149, 150]. 
This analysis suggested three structural sub domains: a 
fixed core domain (aa 100-287), a mobile lid domain (aa 
Figure 3: PHGDH and sPHGDH in vitro activity. (A) Schematic representation of the biochemical PHGDH activity measurement. 
Enzymatic activity of human recombinant PHGDH or sPHGDH was measured in the direction of 3-PG oxidation to PHP by coupling the 
enzymatic reaction to the diaphorase-catalysed reduction of resazurin to the fluorescent product resorufin. The red fluorescent product, 
resorufin, was detected by monitoring emission at 580 nm upon excitation at 540 nm. (B) In vitro activity of PHGDH and sPHGDH. 
Enzymatic activity of PHGDH and sPHGDH was measured in the presence of 140 μM 3-PG and 25 μM NAD+ using 75 nM purified 
human PHGDH or sPHGDH. The propagation of the reaction was followed over time for 40 minutes after the addition of NAD+. Analysis 
was performed in GraphPad Prism by determining the initial velocity from the slope of increase in fluorescence over time and corrected 
for baseline increase in fluorescence in the absence of protein. (C) Inhibition of PHGDH/sPHGDH activity by ADPR. Enzymatic activity 
of PHGDH and sPHGDH was measured in the presence of increasing concentrations of ADPR (0.5 – 120 μM). Per cent inhibition was 
calculated by comparison to control samples containing no inhibitor (0 % inhibition) and a control without enzyme (100 % inhibition). 
Graph represents mean and standard deviation of three independent experiments with two intra-assay repeats. Data were analysed using 
nonlinear regression (log (inhibitor) vs. response – variable slope) in GraphPad Prism. (D) Mechanism of PHGDH inhibition by ADPR. 
In vitro activity of recombinant human PHGDH in the presence of varying concentrations of cofactor NAD+ (0 – 150 μM) and constant 
substrate concentration (3-PG, 140 μM), and varying amounts of ADPR (0 - 120 μM). Initial velocity was determined from the increase 
in fluorescence over time, and plotted against increasing concentrations of NAD+. The data were fitted to the mixed-model equation in 
GraphPad Prism. A representative graph of three independent experiments is shown with each condition assessed in duplicate. The initial 
velocity was determined as the mean of the three independent experiments.
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9-93 and aa 289-301) and a hinge domain (aa 94-99 and aa 
302) (Figure 6A). Interestingly, superposition of the two 
conformations with and without bound L-tartrate showed 
that the lid domain had rotated by 29° upon substrate 
binding (Figure 6B). Upon closer inspection of the 
substrate-binding sites in both chains, distinct movements 
of the amino acids involved in L-tartrate binding were 
evident. In the presence of L-tartrate, a subset of amino 
acids either moved into the binding site (Arg74, Arg53), 
so that Arg53 interacted with O and O1 of L-tartrate 
and Arg74 with O2 and O5 of the substrate analogue, or 
adopted alternate rotamers that oriented their side-chains 
towards the binding site (Gln291) (Figure 6C and 6D).
NAD+ analogues can substitute for NAD+ in the 
catalytic reaction of PHGDH
NAD+ analogues were used to study the effect of 
changes around the nicotinamide-binding subsite on 
the enzymatic activity and stability of PHGDH and to 
Figure 4: Structures and synergistic binding with NAD+ to PHGDH of the substrate 3-PG and the product 3-PHP and 
their analogues. (A) For 3-phosphoglycerate (upper panel) as well as 3-phosphohydroxypyruvate (lower panel) and its analogues,the 
2-hydroxypropanoic acid, or 2-oxopropanoic acid respectively, moieties are highlighted in bold. (B) Thermal denaturation of 1 μM PHGDH 
in the presence of 0.2 mM NAD+ or 0.2 mM NADH alone and in combination with 0.2 mM substrate analogues, was measured. Graphs 
represent mean and standard deviation of three independent experiments with two replicates per experiment. Statistical analysis was 
performed in GraphPad Prism (two way ANOVA). *= p < 0.1, *** = p < 0.005, **** = p < 0.0005.
Figure 5: Binding of NAD+ and L-tartrate to sPHGDH. Human sPHGDH structure showing interactions with cofactor NAD+ 
(A) and substrate analogue L-tartrate (B). (A) sPHGDH and NAD+ are coloured by atom type and hydrogen bonds are indicated as dashed 
lines. (B) sPHGDH and L-tartrate are coloured by atom type with carbon atoms of sPHGDH coloured in coral (lid domain) and light blue 
(core domain) depending on which domain they belong to. Electron density map (2Fo-Fc map) for NAD
+ and L-tartrate is contoured at 1.3 
electrons/A3 and is shown as orange mesh.
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understand what functional groups would be tolerated in 
this part of the cofactor-binding site.
Thionicotinamide (TAD), acetylpyridine (APAD) 
and Thionicotinamide (TAD), acetylpyridine (APAD) and 
pyridinealdehyde adenine dinucleotide (PAD) were tested 
in the enzyme activity assay in place of NAD+ and all were 
found to allow the enzymatic reaction to proceed while not 
affecting the enzymatic activity of the recycling enzyme 
(Supplementary Figure 3). In particular, TAD was found 
to be very similar to NAD+ in terms of maximum velocity 
(Vmax) (10.0 and 7.2 pmol min
-1 for TAD and NAD+ 
respectively) and kcat (0.45 and 0.32 min
-1 for TAD and 
NAD+ respectively). In contrast, Vmax for APAD and PAD 
was higher than NAD+. APAD showed a 10-fold increase 
in kcat compared to NAD
+, whereas PAD showed a slightly 
reduced kcat (Figure 7A and 7B, Table 2).
All cofactor analogues tested could replace NAD+ and 
sustain PHGDH activity. In order to compare their binding 
affinities with NAD+, a DSF assay was performed (Figure 
7C). All the cofactor analogues on their own stabilized 
PHGDH less than NAD+, with APAD showing no increase 
in Tm, suggestive of relatively low affinity of PHGDH for 
APAD in the absence of 3-PG (1). This is concordant with 
the weaker affinity of PHGDH for APAD giving a higher 
Table 1: Diffraction data collection and refinement statistics (molecular replacement)
sPHGDH – NAD+ and L-tartrate (PDB ID: 5N6C)
Data collection
Beamline Diamond Light Source, I04-1
Wavelength (Å) 0.92
Space group P 21
Cell dimensions
 a, b, c (Å) 43.5, 109.7, 66.9
 α, β, γ (°) 90.0, 94.0, 90.0
No. unique reflections 29527 (2224)
Resolution (Å) 57.0 - 2.2 (2.3 – 2.2)
Rmerge 0.06 (0.59)
I/σI 12.6 (2.3)
Completeness (%) 98.0 (98.8)
Redundancy 3.8
Refinement
Ligand NAD+ and L-tartrate
Resolution (Å) 66.7-2.3
No. reflections (all/free) 27427 / 1319
Rwork / Rfree 0.21 / 0.25
Average B factor (Å2)
 All atoms 26
 Protein 8
 Water 36
R.m.s. deviations
 Bond lengths (Å) 0.02
 Bond angles (°) 2.21
Molprobity
Ramachandran favoured (%) 96.0
Values in parentheses are for highest-resolution shell. R.m.s., root-mean-square.
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Km compared to the natural cofactor NAD
+ in the in vitro 
enzyme activity assay. In combination with 3-PG, all 
analogues showed the same synergistic behavior, increasing 
the Tm of PHGDH to the same extent as NAD
+. This result 
is even more striking considering that the NAD+ analogues 
yielded only small increases in Tm of PHGDH when tested 
in the absence of substrate analogues. This indicates that the 
binding of 3-PG might induce a conformational change of 
the protein that increases accessibility to the cofactor binding 
pocket and permits binding of cofactor analogues or slows 
down their dissociation. Intriguingly, for NAD+ analogues 
in combination with other substrate analogues, a significant 
change in Tm was only seen for PAD together with α-KG 
(ΔTm = 2.6 ± 0.7 °C) (Figure 7C, Supplementary Figure 4).
Figure 6: Analysis of the domain movement in a co-crystal structure of sPHGDH with L-tartrate and NAD+. The protein 
crystal structure was analysed using the DynDom web server. (A) Structure of sPHGDH chain A with different domains highlighted: 
fixed domain in blue, mobile domain in orange, hinge domain in green. The cofactor NAD+ is shown as spheres coloured by atom type. 
(B) Superposition of the two molecules in the ASU. Structures containing L-tartrate and without L-tartrate are coloured in purple and 
grey, respectively. NAD+ and L-tartrate are coloured by atom type and displayed as spheres. (C) Changes in the substrate-binding site 
of sPHGDH observed upon binding of L-tartrate. Chain A (light blue) with L-tartrate (purple) and NAD+ (grey) bound to the active site 
superposed onto chain B (lilac) with only NAD+ bound to the active site. Movement of individual amino acids involved in L-tartrate binding 
indicated with orange arrows. (D) Chain A (light blue/gold) with L-tartrate bound (purple) superposed onto chain A (grey) of sPHGDH 
with NAD+ and D-malate bound (cyan) (PDB 2G76). New hydrogen bonds are formed between the amino acids highlighted in gold and 
the additional OH-group of L-tartrate compared to binding of D-malate. Electron density map (2F0-Fc map) for L-tartrate is contoured at 1.3 
electrons/A3 and is shown as blue mesh.
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DISCUSSION
A crystal structure of a truncated form of human 
PHGDH comprising the nucleotide- and substrate-binding 
regions revealed D-malate, a substrate analogue, bound to 
the substrate-binding pocket. Investigation of the binding 
of malate and other substrate analogues of 3-PG and PHP 
in a DSF assay highlighted L-tartrate and α-KG as weak 
stabilizers of PHGDH, whereas the natural substrate 3-PG 
gave a substantial increase in Tm.
E. coli PHGDH can utilize α-KG as a substrate, 
although human as well as rat and M. tuberculosis 
PHGDH have been reported not to share this ability [8]. 
Nevertheless, a recent study found human PHGDH to be 
able to catalyze the NADH-dependent reduction of α-KG 
to D-2-hydroxyglutarate, an oncometabolite associated 
with brain cancer and acute myeloid leukemia [11]. In this 
context our work shows for the first time the biochemical 
basis for this finding, by confirming the binding of α-KG 
to human PHGDH, consistent with the suggestion that 
PHGDH could effect this cancer-linked transformation 
in vivo. This result confirms that human PHGDH 
displays a degree of substrate promiscuity and can bind 
alternative substrates to the primary substrate 3-PG. This 
promiscuity could be of special relevance in determining 
the role of PHGDH in certain cancer forms that depend on 
PHGDH activity (often associated with elevated PHGDH 
expression levels) beyond its role in serine synthesis. 
In such cancer cell lines PHGDH depletion resulted in 
decreased proliferation effects, which could not be rescued 
by increased serine supplementation to the media [2, 4].
Binding of substrate analogues was also investigated 
in combination with the cofactor NAD+ as possible 
interdependence of substrate and cofactor binding is 
suggested by the close proximity of their respective 
binding sites. Indeed, the combination of 3-PG and NAD+ 
increased the Tm significantly, and by more than the simple 
addition of the effects seen with the two compounds 
Figure 7: Enzyme kinetic data for PHGDH with various substrate analogues. In vitro PHGDH activity assay containing 
recombinant human PHGDH and increasing concentrations of NAD+ or TAD (A) or the NAD+ analogues PAD or APAD (B). The increase 
in fluorescence due to conversion of NAD+ to NADH was measured and initial velocity determined by linear regression. The initial 
velocity was plotted against cofactor/ cofactor analogue concentration and data fitted to a Michaelis-Menten model. All curve fitting was 
performed using GraphPad Prism. Data plotted represents mean and standard deviation of two independent experiments with two replicates 
per experiment. (C) Change in Tm (ΔTm) of PHGDH upon addition of NAD+ analogues in combination with substrate/ substrate analogues. 
Thermal denaturation of 1 μM PHGDH in the presence of 0.2 mM NAD+ analogue in combination with 0.2 mM substrate/ product 
analogue. Graphs represent mean and standard deviation of at least two independent experiments with two replicates per experiment. 
Statistical analysis was performed in GraphPad Prism (two way ANOVA). **** = p < 0.0001.
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separately. The same was found to be true for DL-malate 
where the presence of NAD+ appeared to be necessary for 
the substrate analogue to bind at all, although NAD+ was 
able to bind on its own. Thus for DL-malate and NAD+, 
cofactor binding seems to be a necessary event to permit 
binding of the substrate analogue, whereas for 3-PG a 
different obligatory binding order is suggested based 
on the DSF data, since 3-PG alone is able to provide a 
substantial Tm shift. Interpretation of these results might 
be complicated by the observation that PHGDH appears 
to co-purify with NAD+ or NADH, as suggested by the 
relatively high OD
260
:OD
280
 ratio of 0.9 for untreated 
preparations of PHGDH compared to a reported ratio 
of OD
260
:OD
280
 of 0.57 for pure protein [15]. Taking 
into account that a certain amount of cofactor is already 
bound to the purified protein when we performed the 
experiments, it seems likely that the order of binding must 
be cofactor before substrate. To support this preferred 
binding order, our co-crystal structure of sPHGDH with 
L-tartrate, revealed one subunit containing L-tartrate 
and NAD+, and one subunit containing only NAD+. 
Comparison of the two molecules showed that in the 
presence of L-tartrate a movement of the lid domain 
towards a more closed substrate pocket had occurred, 
consistent with the hypothesis that the substrate binds 
after the cofactor. For PHGDH from M. tuberculosis, 
another type I PHGDH, the substrate is reported to bind 
before the cofactor, although this catalytic mechanism was 
investigated in the (non-physiological) direction of PHP 
reduction [8].
An understanding of the promiscuity of the substrate 
and co-factor binding sites in PHGDH is critical to define 
its role, not only in healthy and disease models, but also for 
the development of PHGDH inhibitors targeting the active 
site. Using DSF, we have shown that several substrate or 
product analogues are able to bind to the substrate-binding 
site. However, we also used NAD+ analogues, such as 
APAD, TAD and PAD to investigate if they would be able 
to interact with PHGDH. These analogues are known to be 
able to replace NAD+ in reactions catalyzed by a variety 
of enzymes [16, 17] and this was also found to be true for 
PHGDH. In particular, APAD showed a ten-fold higher 
apparent kcat than NAD
+, which is likely due to its higher 
oxidation potential, which in turn may support a higher 
rate in the redox reaction [18]. Interestingly, analysis of 
the binding affinities of the cofactor analogues by DSF 
showed that none of the analogues stabilized PHGDH to 
the same extent as NAD+, with e.g. no stabilization seen 
Table 2: Summary of calculated parameters of PHGDH enzyme activity. aR is used to denote the ADP-ribose moiety. 
b ΔTm of PHGDH in combination with 3-PG (200 μM) and cofactor (analogue) (200 μM) compared to buffer only control. 
3-PG (200 μM) alone results in an increase in Tm of PHGDH of 2.5 ± 0.6 °C.
Structure of 
nicotinamide moietya
Vmax (pmol/min) kcat (min-1) Km (μM) ΔTmb (-Buffer control) 
(°C)
NAD+ 7.2 ± 0.4 0.3 ± 0.0 5.3 ± 1.6 4.5 ± 0.8
TAD 10.0 ± 0.6 0.45 ± 0.0 11.8 ± 3.5 4.6 ± 0.6
APAD 68.4 ± 1.9 3.04 ± 0.1 39.4 ± 4.9 4.8 ± 1.1
PAD 46.8 ± 3.8 0.21 ± 0.2 147.7 ± 34.9 5.1 ± 1.2
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with APAD. This is consistent with an elevated Km (i.e. 
lower affinity for the substrate) for APAD as a cofactor 
analogue in the sPHGDH-catalyzed reaction. If release of 
the product of APAD reduction is rate limiting, this lower 
affinity might also contribute to a higher apparent kcat for 
APAD relative to NAD+. While cooperative stabilization of 
PHGDH by most substrates was dependent on the identity 
of the cofactor analogue used, all cofactor analogues were 
able to exert a stabilizing effect in combination with 3-PG.
With the exception of α-KG in combination 
with PAD, a cooperative stabilization of PHGDH was 
not observed with other substrate analogue/co-factor 
analogue combinations. A significant increase in the Tm 
of PHGDH in the presence of PAD and α-KG, but not 
upon combination of α-KG with other cofactor analogues, 
is unlikely to be due to a difference in the electron 
distribution around the aromatic ring: the aldehyde 
function of PAD, like the amide substituent of NAD+ has 
an electron withdrawing inductive and resonance effect 
on the aromatic ring. Therefore it is more likely due to 
the difference in the size of the moiety, with hydrogen 
replacing the NH
2
 group in PAD. This would also explain 
why the effect is only seen with PAD and not with APAD 
and TAD, with the latter two having a methyl group or an 
NH
2
 group at the position of the hydrogen, respectively.
In summary, we have investigated the substrate 
binding of PHGDH by solving the crystal structure of 
sPHGDH with and without the substrate analogue L-
tartrate bound to the catalytic site, revealing a distinct 
domain movement upon substrate binding. We have 
shown that different substrate analogues are tolerated in 
the protein’s binding site, and that substrate binding can 
increase the thermal stability of PHGDH. The cofactor-
binding site also tolerates the binding of NAD+ analogues 
with modifications around the nicotinamide moiety, all of 
which are able to both bind and sustain enzymatic activity. 
These findings support the hypothesis that PHGDH may 
be involved in more enzymatic reactions than its primary 
role in 3-PG oxidation and we suggest that such additional 
roles could be especially relevant to explain the role of 
PHGDH in cancer. The substrate and cofactor promiscuity 
we have seen with PHGDH suggests that substrate or co-
factor competitive inhibitors may well be tolerated in 
the PHGDH active site, opening up new approaches for 
the development of PHGDH inhibitors. Exploring this 
strategy may be timely, since other approaches to PHGDH 
inhibition have already been shown to reduce cancer 
progression in mice.
MATERIALS AND METHODS
Preparation of recombinant human PHGDH and 
sPHGDH
pNIC28-Bsa4 plasmids containing the human 
PHGDH cDNA encoding the full-length enzyme (aa 
1-533) as well as a truncated version (sPHGDH, aa 3-314) 
were kindly donated by Wyatt Yue (SGC Oxford, Oxford, 
UK). Both plasmids are fused with an N-terminal His6-
tag and a Tobacco Etch Virus (TEV) protease recognition 
site. The proteins were expressed in E. coli Rosetta (DE3) 
grown in TB medium (Sigma Aldrich, St. Louis, MO, 
USA) containing 50 μg/mL kanamycin and the purification 
protocol adapted from SGC Oxford (http://www.thesgc.
org/structures/2g76#mand). The bacterial cells were 
grown at 37 °C to an optical density at 600 nm of 0.8-0.9. 
PHGDH/ sPHGDH expression was induced by addition of 
isopropyl β-D-1-thiogalactopyranoside (IPTG) to a final 
concentration of 0.5 mM. Cells were grown for 18 hours at 
25 °C before harvesting by centrifugation and subsequent 
resuspension in 50 mM NaH
2
PO
4
, pH 8, 10 mM imidazole, 
300 mM NaCl, 0.5 mM TCEP, 0.01 mg/mL DNase, 0.05 
mg/mL RNase, 0.25 mg/mL lysozyme, 5 mM MgCl
2
 and 
protease inhibitor. The cell suspension was sonicated on 
ice, followed by centrifugation. The lysate was applied 
to a HisTrap Ni-Sepharose column and the proteins 
eluted with an imidazole gradient to a maximum of 250 
mM imidazole. The His6-tag was cleaved by incubation 
with TEV protease at a mass ratio of 1:25 (protease: 
protein) at 4 °C for 16 hours. The mixture was applied 
to a gravity flow column containing Ni-Sepharose beads 
to capture TEV protease and His6-fragments. The protein 
was further purified by size exclusion chromatography 
on a SuperdexTM 75 26/60 column (GE Healthcare) in 25 
mM HEPES, pH 7.5, 100 mM NaCl, 0.5 mM TCEP. The 
protein containing fractions were combined, concentrated 
and buffer exchanged into low salt buffer (20 mM Tris, pH 
8, 40 mM NaCl, 0.5 mM TCEP) using a PD-10 column 
(GE Healthcare, Little Chalfont, UK). The protein was 
further purified by anion exchange chromatography using 
a linear gradient up to 1 M NaCl (high salt buffer).
Enzyme activity assay
The enzymatic activity of PHGDH or its catalytic 
domain (sPHGDH) was measured in the direction of 3-PG 
oxidation to PHP by coupling the reaction with a resazurin 
reduction reaction to allow fluorescence detection 
[19]. The assay mixture contained 18 mM BIS TRIS 
propane, pH 7.5, 1.7 mM EDTA, pH 7.5, 10 μM Triton 
X-100, 3.3 mM glutathione, 140 μM 3-PG (Santa Cruz 
Biotechnology, Dallas, Texas, USA), 25 μM NAD+ and 75 
nM purified human PHGDH or sPHGDH. The assay was 
performed in black 96-well plates (Sterilin Ltd, Gwent, 
UK) in 150 μL total volume of which 25 μL was the NAD+ 
recycling mixture containing the diaphorase and resazurin 
(Amplite Fluorimetric assay buffer, Stratech Scientific 
Ltd., Suffolk, UK). The fluorescence was measured 
on an Omega Platereader (BMG Labtech, Ortenberg, 
Germany) over 40 – 50 minutes. Analysis was performed 
in GraphPad Prism by determining the initial velocity 
from the slope of increase in fluorescence over time. 
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The initial velocity was corrected for baseline increase in 
fluorescence in the absence of protein.
Isothermal titration calorimetry
ITC experiments were performed in 25 mM HEPES, 
pH 7.5, 100 mM NaCl, 0.5 mM TCEP at 25 °C in a 
MicroCal iTC200 instrument (GE Healthcare). To remove 
residual bound cofactor, sPHGDH was incubated with 0.5 
equivalents of activated charcoal for 30 minutes at room 
temperature prior to performing the ITC experiments. The 
charcoal was removed by centrifugation at 13 000 x g, 4 
°C for 10 minutes, followed by filtering the supernatant 
through a PD10 column. 1 x 0.5 μL, followed by 17 x 2 μL 
injections of ligands into protein with 120 seconds spacing 
between the injections was conducted. The thermodynamic 
parameters of the reactions were determined following 
peak integration and best-fit of data to the one-site binding 
model using ORIGIN version 7.0 (OriginLab).
Differential scanning fluorimetry
The assay mixture contained 25 mM HEPES, pH 
7.5, 100 mM NaCl, 0.5 mM TCEP, 1 x Sypro Orange 
(Thermo Fisher Scientific, Waltham, MA, USA) and 1 
μM protein. Ligand solutions were prepared in 25 mM 
HEPES, pH 7.5, and added at 200 μM to the assay. The 
heat denaturation curves were recorded using an RT-PCR 
instrument (ViiA7, Applied Biosystems, Warrington, UK). 
The temperature was increased by 3 °C/min starting at 
25 °C up to 95 °C and the fluorescence of Sypro Orange 
measured with excitation and emission wavelengths of 
470 and 570 nm, respectively. Analysis was performed 
using the Boltzmann equation in GraphPad Prism.
Crystallization, X-ray crystallographic data 
collection, structure determination and analysis
For co-crystallization, sPHGDH at 15 mg/mL (in 
25 mM HEPES, pH 7.5, 100 mM NaCl, 0.5 mM TCEP) 
was mixed with substrate analogue and incubated 
at 4 °C for 16 hours. The mixture was screened for 
crystallization against sparse matrix screens: Index 
(Hampton Research, Aliso Viejo, CA, USA), JCSG+, 
Structure, Proplex and Morpheus (all from Molecular 
Dimensions, Newmarket, Suffolk, UK) in 96-well 
MRC crystallization plates (Molecular Dimensions, 
Newmarket, Suffolk, UK) by the sitting drop vapour 
diffusion method. Plates were set up using a Mosquito 
LCP liquid handler (TTP Labtech, Melbourn, UK) 
with two drops of 300 nL protein (15 mg/mL) mixed 
with 300 or 600 nL precipitant and a shared reservoir 
solution of 70 μL precipitant. Crystal trials were 
stored at 4 or 20 °C. Crystals thus obtained were cryo-
protected in reservoir solution (0.1 M Bis TRIS buffer, 
pH 6.5, 0.3 M NH
4
Ac, 17 % PEG3350) supplemented 
with ligand and 20 % (w/v) PEG400 before being 
flash cooled in liquid nitrogen. Diffraction data were 
collected on beamline I04, Diamond Light Source. Data 
were processed using xia2, an automated combination 
of XDS [20], XSCALE [20] and programs from the 
CCP4 suite [21] and used for molecular replacement 
with PHASER [22], run through the CCP4i2 GUI, using 
the published structure of human PHGDH (PDB 2G76) 
as the search model. The structure was refined using 
iterative cycles of manual model correction in COOT 
[23] followed by refinement with Refmac5 [24] within 
CCP4 [21]. Models were validated using the validation 
tools available in COOT, and MolProbity [25]. Figures 
were produced using CCP4mg [26].
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